Meeting
2013 Genitourinary Cancers Symposium
Analysis of putative resistance mechanisms in recent treatments targeting the androgen receptor in castration-resistant prostate cancer (CRPC).
Authors
Paul Thelen
Georg-August-University, Goettingen, Germany
Paul Thelen , Eiko Walleck , Felix Bremmer , Lutz Trojan , Arne Strauß
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer
Citation
J Clin Oncol 31, 2013 (suppl 6; abstr 130)
DOI
10.1200/jco.2013.31.6_suppl.130
Abstract #
130
Poster Bd #
H13
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
In vitro reproduction and explanation of an abiraterone acetate withdrawal phenomenon.
First Author: Paul Thelen
Poster
2016 ASCO Annual Meeting
Galeterone in treatment-naïve patients with castration-resistant prostate cancer with C-terminal androgen receptor loss: Results from ARMOR2.
First Author: Mary-Ellen Taplin
Poster
2020 Genitourinary Cancers Symposium
Gene expression in circulating tumor cells (CTC) and plasma androgen receptor (AR) gene copy number (CN) for castration-resistant prostate cancer (CRPC) patients (pts) treated with cabazitaxel.
First Author: Giorgia Gurioli
Poster
2018 Genitourinary Cancers Symposium
A phase Ib/II trial of indomethacin and enzalutamide to treat castration-resistant prostate cancer (CRPC).
First Author: Chong-xian Pan